4[23]Dube M P, Johnson D L, Currier J S, et al. Protease inhibitor-associated hyperglycaemia[J]. Lancet, 1997, 350: 713-714.
5[24]Blanche s, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues[J]. Lancet, 1999, 354: 1084-1089.
6[25]Ciesielski C A, Metler R P, Msph R N. Duration of time betneen exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus[J]. Am J Med, 1997, 102(5B): 115-116.
7[26]Busch M P, Satten G A. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure[J]. Am J Med, 1997, 102(5B): 117-124.
8[27]Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous of human immunodeficiency virus and hepatitis C virus from a needle-stick injury[J]. N Engl J Med, 1997, 336(13): 919-922.
9[28]Descanms D, Flandre P, Clavez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy[J]. JAMA, 2000, 283(2): 205-211.
10[29]Devereux H L, Youle M, Johnson M A, et al. Rapid decline in detectability of HIV-I drug resistance mutations after stopping therapy[J]. AIDS, 1999, 13(18): F123-127.
